VX-950 and Peginterferon for Hepatitis C

A Phase 1b Viral Kinetic Study of VX-950 and Peginterferon in Hepatitis C

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00251199

Enrollment

Registered

2005-11-09

Start date

2005-10-31

Completion date

2006-03-31

Last updated

2007-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Brief summary

VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.

Interventions

DRUGVX-950

DRUGpeginterferon

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Inclusion criteria

* infected with Hepatitis C virus

Exclusion criteria

* contraindications to peginterferon therapy

Design outcomes

Primary

Measure	Time frame
Viral kinetics	—

Secondary

Measure	Time frame
Assess the safety of VX-950 in combination with peginterferon	—

Countries

Germany, Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026